Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William C Olson

Showing results (41-50 of 73) with videos related to

Pageof 8
Sort By:
The Journal of Infectious Diseases|April 10, 2010
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibodyJeffrey M Jacobson, Melanie A Thompson, Jacob P Lalezari, et al.
AIDS Research and Human Retroviruses|June 27, 2006
Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype ASimon Beddows, Marc Kirschner, Lila Campbell-Gardener, et al.
AIDS Research and Human Retroviruses|July 3, 2007
Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimersSai Prasad N Iyer, Michael Franti, Ammie A Krauchuk, et al.
Plos One|May 1, 2012
Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell cultureGlen A Coburn, Danielle N Fisch, Sameer M Moorji, et al.
Virology|November 28, 2006
A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120Simon Beddows, Michael Franti, Antu K Dey, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2010
Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adultsJeffrey M Jacobson, Jacob P Lalezari, Melanie A Thompson, et al.
Journal for Immunotherapy of Cancer|January 23, 2021
Preclinical PET imaging with the novel human antibody <sup>89</sup>Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissuesMarcus P Kelly, Sosina Makonnen, Carlos Hickey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particlesStacie M Goldberg, Shirley M Bartido, Jason P Gardner, et al.
Journal of Virology|December 30, 2011
Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responsesMark Melchers, Ilja Bontjer, Tommy Tong, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2003
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapyNorbert Schülke, Olga A Varlamova, Gerald P Donovan, et al.
Pageof 8

Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
The Journal of Infectious Diseases|April 10, 2010
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibodyJeffrey M Jacobson, Melanie A Thompson, Jacob P Lalezari, et al.
AIDS Research and Human Retroviruses|June 27, 2006
Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype ASimon Beddows, Marc Kirschner, Lila Campbell-Gardener, et al.
AIDS Research and Human Retroviruses|July 3, 2007
Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimersSai Prasad N Iyer, Michael Franti, Ammie A Krauchuk, et al.
Plos One|May 1, 2012
Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell cultureGlen A Coburn, Danielle N Fisch, Sameer M Moorji, et al.
Virology|November 28, 2006
A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120Simon Beddows, Michael Franti, Antu K Dey, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2010
Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adultsJeffrey M Jacobson, Jacob P Lalezari, Melanie A Thompson, et al.
Journal for Immunotherapy of Cancer|January 23, 2021
Preclinical PET imaging with the novel human antibody <sup>89</sup>Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissuesMarcus P Kelly, Sosina Makonnen, Carlos Hickey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particlesStacie M Goldberg, Shirley M Bartido, Jason P Gardner, et al.
Journal of Virology|December 30, 2011
Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responsesMark Melchers, Ilja Bontjer, Tommy Tong, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2003
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapyNorbert Schülke, Olga A Varlamova, Gerald P Donovan, et al.
Pageof 8